Physician profile
Peter M Gallogly
NPI 1053476226
$2,241.90
in general payments reported to CMS, 2019-2025
30 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $366 · 2021: $497 · 2022: $334 · 2023: $447 · 2024: $224 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876 · Education: $59.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.38 |
| Education | $59.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.12 | 2021-2025 | |
| Pfizer INC. | $176.62 | 2019-2023 | |
| Allergan, INC. | $160.65 | 2019-2020 | |
| Orexo US, INC. | $143.71 | 2019-2023 | Zubsolv |
| Lilly USA, LLC | $121.76 | 2020-2025 | Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $96.90 | 2022-2024 | Trelegy Ellipta |
| Alkermes, INC. | $69.69 | 2019-2023 | Vivitrol |
| Axsome Therapeutics, INC. | $67.19 | 2025 | Auvelity |
| Indivior INC. | $65.95 | 2024 | Sublocade |
| Jazz Pharmaceuticals INC. | $62.73 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $46.25 | 2020-2024 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $36.29 | 2021 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Amneal Pharmaceuticals LLC | $34.33 | 2023 | Lyvispah |
| Abbott Laboratories | $29.54 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.17 | 2021 | |
| Grifols USA, LLC | $22.89 | 2021 | |
| Boston Scientific Corporation | $22.36 | 2023 | Superion Indirect Decompression System |
| Photonicare INC | $22.36 | 2023 | Otosight Middle Ear Scope |
| Braeburn INC. | $22.24 | 2025 | Brixadi |
| Inspire Medical Systems, INC. | $19.79 | 2023 | Inspire |
| Novo Nordisk INC | $19.72 | 2020 | |
| Hologic Sales and Service, LLC | $17.84 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.59 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.31 | 2025 | Nuzyra |
| Acerus Pharmaceuticals Corporation | $15.06 | 2022 | |
| Medtronic, INC. | $14.75 | 2023 | Closurefast |
| Kvk-Tech, INC. | $12.89 | 2019 | |
| Uswm, LLC | $12.73 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gallogly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.